Search results for: 'Drug Discovery and Early Development Outsourcing Market'

This research service encompasses a comprehensive analysis of RNA therapy industry from the following perspectives: • Industry Drivers and Challenges • Technology Snapshot and Trends • Clinical Pipeline Analysis • Overview of the IP Landscape • Innovator Profiles • Future Roadmap The RNA therapy platforms covered include: • Splice-Switching Oligon...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) covers insights across biomanufacturing, targeted drug delivery, imaging, precision medicine and biologics innovations.The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and ...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) comprise innovation insights across antibody and cellular therapies. The study also encompasses recent innovations in liquid biopsy tests, drug delivery and drug discovery platforms.The Life Science, Health & Wellness TOE will feature disruptive technology advan...

This Radar examines the North American CXM landscape. It includes outsourcing services alone, excluding operations performed in-house and in shared service centers. Furthermore, it encompasses revenue associated with customer interactions that originate in the United States or Canada, regardless of the fulfillment model. This includes onshore, near...

The World Drug Discovery Technologies market is a dynamic marketplace with substantial opportunity. This study focuses on the market dynamics of 2005, by looking at the four major contributors to this market: top 20 pharmaceutical companies, biotechnology companies, top 5 agribiotech companies, and the NIH budget. The study also provides detailed ...

Immuno-oncology (I-O) therapies target tumors by harnessing the host s immune system. With the growing incidence and prevalence of various types of aggressive and refractory cancers, the next-generation I-O therapy pipeline has witnessed significant growth. Chimeric antigen receptor (CAR)-T cell therapy and tumor-targeted antibody therapies, includ...

This Frost Radar™ analyzes the competitive landscape of the antibody-drug conjugate (ADC) contract development and manufacturing organization (CDMO) market. Companies provide the foundational manufacturing and development services for what has become one of the most dynamic and valuable therapeutic modalities in oncology. The success of the ADC rev...

By 2023, biologics constituted 44% of the therapeutic pipeline, with antibodies and recombinant proteins as leading categories. Nevertheless, advancements in these fields decelerated, with most of the expansion happening in heterologous cell treatments, synthetic nucleic acids, and viruses. The global biologics pipeline will shift toward more compl...

This study explores the transformative potential of organoid technologies in advancing cancer research, precision medicine, and drug discovery. Organoids—3D cell culture systems derived from patient tumors—preserve tumor heterogeneity and provide physiologically relevant models for studying cancer biology, therapeutic response, and resistance mecha...